UBCS039

UBCS039 is the first synthetic, specific Sirtuin 6 (SIRT6) activator, inducing autophagy in human tumor cells, with an EC50 of 38 μM[1].

Signaling Pathways >> Epigenetics >> Sirtuin

Research Areas >> Cancer

Signaling Pathways >> Cell Cycle/DNA Damage >> Sirtuin

SIRT6:38 μM (EC50)

UBCS039 (75 μM, 48 or 72 hours) induces deacetylation of SIRT6-targeted histone H3 sites in human cancer cells[2]. UBCS039 leads to autophagosome accumulation in human cancer cells[2]. UBCS039 induces autophagy via AMP-activated protein kinase (AMPK) signaling pathway activation[2]. Western Blot Analysis[2] Cell Line: Human H1299 cells. Concentration: 75 μM. Incubation Time: 48 and 72 hours. Result: Induced deacetylation of SIRT6-targeted histone H3 sites in human H1299 cells. Western Blot Analysis[2] Cell Line: Human H1299 cells. Concentration: 75 μM. Incubation Time: 48 and 72 hours. Result: Induced deacetylation of SIRT6-targeted histone H3 sites in human H1299 cells. Cell Proliferation Assay[2] Cell Line: Human H1299 cells. Concentration: 100 μM. Incubation Time: 48 and 72 hours. Result: Led to a strong decrease of cell proliferation in a dose-dependent manner when compared with control or DMSO-treated cells, starting from day 3 of growth (48 h after treatment) in both H1299 and HeLa cell lines.

[1]. Led to a strong decrease of cell proliferation in a dose-dependent manner when compared with control or DMSO-treated cells, starting from day 3 of growth (48 h after treatment) in both H1299 and HeLa cell lines.

[2]. Sara Iachettini, et al. Pharmacological activation of SIRT6 triggers lethal autophagy in human cancer cells. Cell Death and Disease (2018) 9:996.